Jun 10, 2014Clinical Study Results Demonstrate Therapeutic Advantages Of The Boston Scientific Vercise™ DBS System For Patients With Parkinson's DiseaseData Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
Jun 4, 2014Boston Scientific Initiates the RESPOND Post Market Registry Evaluating Clinical Outcomes in Patients Implanted With Lotus™ Valve System
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
May 21, 2014Boston Scientific Lotus™ Valve System demonstrates strong performance and safety profile at six months
Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred Further validating its advanced transcatheter aortic valve implantation (TAVI)...
May 8, 2014New data presented at WIP 2014 demonstrate sustained low back pain relief with the Boston Scientific Precision Spectra™ Spinal Cord Stimulator System
Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision...